Skip to main content

Table 2 Growth-inhibition efficacy data on ovarian cancer cell lines and normal cell lines treated with DAP compounds compiled from individual MTT assay

From: Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs

Cell lines Cisplatin 10 μg/ml (%) Curcumin 100 μM (%) DAP-F (p) 10 μM (%) DAP-F(p)-NOH 10 μM (%) DAP-CF3(P) 10 μM (%) DAP-CF3(P)-NOH 10 μM (%)
A2780 75-85 65-75 80-90 75-85 80-90 80-90
A2780R* 50-60 55-65 85-90 70-80 75-85 70-80
SKOV3 80-90 65-75 80-90 75-85 85-90 75-80
OVCAR3 70-80 65-70 75-80 80-85 75-85 70-80
OV-4 75-80 60-65 75-80 70-80 80-85 80-85
PA-1 65-75 50 65-75 70-75 75-80 75-80
hOSE
CHO
H9C2
HSMC
  1. Cell viability, cell survival and cell proliferation were quantified as means ± SE (N = 8, p ≤ 0.05 versus control) and expressed as percentage of respective untreated controls.  = Moderately toxic; ☺ = Non-toxic; - = not tested.